Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Vulvar Neoplasms 1Vulvar Diseases 1Uterine Cervical Dysplasia 1Rectal Neoplasms 1Papillomavirus Infections 1Colonic Neoplasms 1Carcinoma in Situ 1

Interventions

human papillomavirus vaccine, L1 type 16, 18 30Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 20Papillomavirus Vaccines 9Radiotherapy, Intensity-Modulated 4Cisplatin 4Blood Specimen Collection 4fludarabine 3Vaccines, Synthetic 3Engerix-B 3Cyclophosphamide 3halofantrine 2fludarabine phosphate 2aldesleukin 2Watchful Waiting 2Vaccines 2Patient Navigation 2Paclitaxel 2Light Coagulation 2Interleukin-2 2Imiquimod 2Human Papillomavirus Recombinant Vaccine nonavalent 2Hepatitis A Vaccines 2Fluorouracil 2Electrocoagulation 2Cetuximab 2Carboplatin 2Albumin-Bound Paclitaxel 2utomilumab 1polyphenon E 1infigratinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Papillomavirus Infections × Doxylamine × Clear all
NCT02858310 2026-03-09

E7 TCR T Cells for Human Papillomavirus-Associated Cancers

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
224 enrolled 15 charts
Gynecologic

Carcinoma in Situ, Uterine Cervical Dysplasia, Vulvar Diseases, Vulvar Neoplasms, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡